Skip to main content
Top
Published in: Endocrine 2/2014

01-11-2014 | Original Article

Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation

Authors: Cinzia Puppin, Cosimo Durante, Marialuisa Sponziello, Antonella Verrienti, Valeria Pecce, Elisa Lavarone, Federica Baldan, Antonio Francesco Campese, Amelie Boichard, Ludovic Lacroix, Diego Russo, Sebastiano Filetti, Giuseppe Damante

Published in: Endocrine | Issue 2/2014

Login to get access

Abstract

Abnormal expression of non-coding micro RNA (miRNA) has been described in medullary thyroid carcinoma (MTC). Expression of genes encoding factors involved in miRNA biogenesis results often deregulated in human cancer and correlates with aggressive clinical behavior. In this study, expression of four genes involved in miRNA biogenesis (DICER, DROSHA, DCGR8, and XPO5) was investigated in 54 specimens of MTC. Among them, 33 and 13 harbored RET and RAS mutations, respectively. DICER, DGCR8, and XPO5 mRNA levels were significantly overexpressed in MTC harboring RET mutations, in particular, in the presence of RET634 mutation. When MTCs with RET and RAS mutations were compared, only DGCR8 displayed a significant difference, while MTCs with RAS mutations did not show significant differences with respect to non-mutated tumors. We then attempted to correlate expression of miRNA biogenesis genes with tumor aggressiveness. According to the TNM status, MTCs were divided in two groups and compared (N0 M0 vs. N1 and/or M1): for all four genes no significant difference was detected. Cell line experiments, in which expression of a RET mutation is silenced by siRNA, suggest the existence of a causal relationship between RET mutation and overexpression of DICER, DGCR8, and XPO5 genes. These findings demonstrate that RET- but not RAS-driven tumorigenic alterations include abnormalities in the expression of some important genes involved in miRNA biogenesis that could represent new potential markers for targeted therapies in the treatment of RET-mutated MTCs aimed to restore the normal miRNA expression profile.
Appendix
Available only for authorised users
Literature
1.
go back to reference R.T. Kloos, C. Eng, D.B. Evans, G.L. Francis, R.T. Gagel, H. Gharib, J.F. Moley, F. Pacini, M.D. Ringel, M. Schlumberger, S.A. Wells Jr, Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19, 565–612 (2009)PubMedCrossRef R.T. Kloos, C. Eng, D.B. Evans, G.L. Francis, R.T. Gagel, H. Gharib, J.F. Moley, F. Pacini, M.D. Ringel, M. Schlumberger, S.A. Wells Jr, Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19, 565–612 (2009)PubMedCrossRef
2.
go back to reference R.S. Sippel, M. Kunnimalaiyaan, H. Chen, Current management of medullary thyroid cancer. Oncologist 13(5), 539–547 (2008)PubMedCrossRef R.S. Sippel, M. Kunnimalaiyaan, H. Chen, Current management of medullary thyroid cancer. Oncologist 13(5), 539–547 (2008)PubMedCrossRef
3.
go back to reference S. Leboulleux, E. Baudin, J.P. Travagli, M. Schlumberger, Medullary thyroid carcinoma. Clin. Endocrinol. (Oxf) 61, 299–310 (2004)CrossRef S. Leboulleux, E. Baudin, J.P. Travagli, M. Schlumberger, Medullary thyroid carcinoma. Clin. Endocrinol. (Oxf) 61, 299–310 (2004)CrossRef
4.
go back to reference C. Durante, D. Russo, A. Verrienti, S. Filetti, XL184 (cabozantinib) for medullary thyroid carcinoma. Expert Opin. Investig. Drugs 20(3), 407–413 (2011)PubMedCrossRef C. Durante, D. Russo, A. Verrienti, S. Filetti, XL184 (cabozantinib) for medullary thyroid carcinoma. Expert Opin. Investig. Drugs 20(3), 407–413 (2011)PubMedCrossRef
5.
go back to reference C. Durante, A. Paciaroni, K. Plasmati, F. Trulli, S. Filetti, Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma. Endocrine 44, 334–342 (2013)PubMedCrossRef C. Durante, A. Paciaroni, K. Plasmati, F. Trulli, S. Filetti, Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma. Endocrine 44, 334–342 (2013)PubMedCrossRef
6.
go back to reference E. Chiefari, D. Russo, D. Giuffrida, G.A. Zampa, D. Meringolo, F. Arturi, I. Chiodini, D. Bianchi, M. Attard, V. Trischitta, R. Bruno, P. Giannasio, A. Pontecorvi, S. Filetti, Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma. J. Endocrinol. Investig. 21, 358–364 (1998)CrossRef E. Chiefari, D. Russo, D. Giuffrida, G.A. Zampa, D. Meringolo, F. Arturi, I. Chiodini, D. Bianchi, M. Attard, V. Trischitta, R. Bruno, P. Giannasio, A. Pontecorvi, S. Filetti, Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma. J. Endocrinol. Investig. 21, 358–364 (1998)CrossRef
7.
go back to reference L.M. Mulligan, C. Eng, C.S. Healey, D. Clayton, J.B.J. Kwok, E. Gardner, M.A. Ponder, A. Frilling, C.E. Jackson, H. Lehnert, H.P.H. Neumann, S.N. Thibodeau, A.J. Ponder, Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat. Genet. 6(1), 70–74 (1994)PubMedCrossRef L.M. Mulligan, C. Eng, C.S. Healey, D. Clayton, J.B.J. Kwok, E. Gardner, M.A. Ponder, A. Frilling, C.E. Jackson, H. Lehnert, H.P.H. Neumann, S.N. Thibodeau, A.J. Ponder, Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat. Genet. 6(1), 70–74 (1994)PubMedCrossRef
8.
go back to reference S. Hasani-Ranjbar, M. Amoli, Mutation screening of RET proto-oncogene in a family with medullary thyroid carcinoma, marfanoid habitus and pheochromocytoma; from clinically MEN2B to genetically MEN2A syndrome. Endocrine (2012). doi:10.1007/s12020-012-9610-6 S. Hasani-Ranjbar, M. Amoli, Mutation screening of RET proto-oncogene in a family with medullary thyroid carcinoma, marfanoid habitus and pheochromocytoma; from clinically MEN2B to genetically MEN2A syndrome. Endocrine (2012). doi:10.​1007/​s12020-012-9610-6
9.
go back to reference M. Santoro, R.M. Melillo, F. Carlomagno, G. Vecchio, A. Fusco, Minireview: RET: normal and abnormal functions. Endocrinology 145, 5448–5451 (2004)PubMedCrossRef M. Santoro, R.M. Melillo, F. Carlomagno, G. Vecchio, A. Fusco, Minireview: RET: normal and abnormal functions. Endocrinology 145, 5448–5451 (2004)PubMedCrossRef
10.
go back to reference R. Elisei, B. Cosci, C. Romei, V. Bottici, G. Renzini, E. Molinaro, L. Agate, A. Vivaldi, P. Faviana, F. Basolo, P. Miccoli, P. Berti, F. Pacini, A. Pinchera, Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J. Clin. Endocrinol. Metab. 93, 682–687 (2008)PubMedCrossRef R. Elisei, B. Cosci, C. Romei, V. Bottici, G. Renzini, E. Molinaro, L. Agate, A. Vivaldi, P. Faviana, F. Basolo, P. Miccoli, P. Berti, F. Pacini, A. Pinchera, Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J. Clin. Endocrinol. Metab. 93, 682–687 (2008)PubMedCrossRef
11.
go back to reference C. Mian, G. Pennelli, S. Barollo, E. Cavedon, D. Nacamulli, F. Vianello, I. Negro, G. Pozza, I.M. Boschin, M.R. Pelizzo, M. Rugge, F. Mantero, M.E. Girelli, G. Opocher, Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur. J. Endocrinol. 164, 971–976 (2011)PubMedCrossRef C. Mian, G. Pennelli, S. Barollo, E. Cavedon, D. Nacamulli, F. Vianello, I. Negro, G. Pozza, I.M. Boschin, M.R. Pelizzo, M. Rugge, F. Mantero, M.E. Girelli, G. Opocher, Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur. J. Endocrinol. 164, 971–976 (2011)PubMedCrossRef
12.
go back to reference A. Maliszewska, L.J. Leandro-Garcia, E. Castelblanco, A. Macià, A. de Cubas, G. Goméz-López, L. Inglada-Pérez, C. Álvarez-Escolá, L. De la Vega, R. Letón, Á. Gómez-Graña, I. Landa, A. Cascón, C. Rodríguez-Antona, S. Borrego, M. Zane, F. Schiavi, I. Merante-Boschin, M.R. Pelizzo, D.G. Pisano, G. Opocher, X. Matias-Guiu, M. Encinas, M. Robledo, Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions. Am. J. Pathol. 182, 350–362 (2013)PubMedCrossRef A. Maliszewska, L.J. Leandro-Garcia, E. Castelblanco, A. Macià, A. de Cubas, G. Goméz-López, L. Inglada-Pérez, C. Álvarez-Escolá, L. De la Vega, R. Letón, Á. Gómez-Graña, I. Landa, A. Cascón, C. Rodríguez-Antona, S. Borrego, M. Zane, F. Schiavi, I. Merante-Boschin, M.R. Pelizzo, D.G. Pisano, G. Opocher, X. Matias-Guiu, M. Encinas, M. Robledo, Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions. Am. J. Pathol. 182, 350–362 (2013)PubMedCrossRef
13.
go back to reference R. Ciampi, C. Mian, L. Fugazzola, B. Cosci, C. Romei, S. Barollo, V. Cirello, V. Bottici, G. Marconcini, P.M. Rosa, M.G. Borrello, F. Basolo, C. Ugolini, G. Materazzi, A. Pinchera, R. Elisei, Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 23(1), 50–57 (2013)PubMedCrossRef R. Ciampi, C. Mian, L. Fugazzola, B. Cosci, C. Romei, S. Barollo, V. Cirello, V. Bottici, G. Marconcini, P.M. Rosa, M.G. Borrello, F. Basolo, C. Ugolini, G. Materazzi, A. Pinchera, R. Elisei, Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 23(1), 50–57 (2013)PubMedCrossRef
14.
go back to reference M.A. Valencia-Sanchez, J. Liu, G.J. Hannon, R. Parker, Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 20, 515–524 (2006)PubMedCrossRef M.A. Valencia-Sanchez, J. Liu, G.J. Hannon, R. Parker, Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 20, 515–524 (2006)PubMedCrossRef
16.
go back to reference L. Ma, J. Young, H. Prabhala, E. Pan, P. Mestdagh, D. Muth, J. Teruya-Feldstein, F. Reinhardt, T.T. Onder, S. Valastyan, F. Westermann, F. Speleman, J. Vandesompele, R.A. Weinberg, miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12, 247–256 (2010)PubMedPubMedCentral L. Ma, J. Young, H. Prabhala, E. Pan, P. Mestdagh, D. Muth, J. Teruya-Feldstein, F. Reinhardt, T.T. Onder, S. Valastyan, F. Westermann, F. Speleman, J. Vandesompele, R.A. Weinberg, miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12, 247–256 (2010)PubMedPubMedCentral
17.
go back to reference M.N. Nikiforova, G.C. Tseng, D. Steward, D. Diorio, Y.E. Nikiforov, MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J. Clin. Endocrinol. Metab. 93, 1600–1608 (2008)PubMedCrossRefPubMedCentral M.N. Nikiforova, G.C. Tseng, D. Steward, D. Diorio, Y.E. Nikiforov, MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J. Clin. Endocrinol. Metab. 93, 1600–1608 (2008)PubMedCrossRefPubMedCentral
18.
go back to reference Y. Karube, H. Tanaka, H. Osada, S. Tomida, Y. Tatematsu, K. Yanagisawa, Y. Yatabe, J. Takamizawa, S. Miyoshi, T. Mitsudomi, T. Takahashi, Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 96(2), 111–115 (2005)PubMedCrossRef Y. Karube, H. Tanaka, H. Osada, S. Tomida, Y. Tatematsu, K. Yanagisawa, Y. Yatabe, J. Takamizawa, S. Miyoshi, T. Mitsudomi, T. Takahashi, Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 96(2), 111–115 (2005)PubMedCrossRef
19.
go back to reference G. Grelier, N. Voirin, A.S. Ay, D.G. Cox, S. Chabaud, I. Treilleux, S. Léon-Goddard, R. Rimokh, I. Mikaelian, C. Venoux, A. Puisieux, C. Lasset, C. Moyret-Lalle, Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br. J. Cancer 101, 673–683 (2009)PubMedCrossRefPubMedCentral G. Grelier, N. Voirin, A.S. Ay, D.G. Cox, S. Chabaud, I. Treilleux, S. Léon-Goddard, R. Rimokh, I. Mikaelian, C. Venoux, A. Puisieux, C. Lasset, C. Moyret-Lalle, Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br. J. Cancer 101, 673–683 (2009)PubMedCrossRefPubMedCentral
20.
go back to reference S.I. Chiosea, E.L. Barnes, S.Y. Lai, A.M. Egloff, R.L. Sargent, J.L. Hunt, R.R. Seethala, Mucoepidermoid carcinoma of upper aerodigestive tract: clinicopathologic study of 78 cases with immunohistochemical analysis of Dicer expression. Virchows Arch. 452, 629–635 (2008)PubMedCrossRef S.I. Chiosea, E.L. Barnes, S.Y. Lai, A.M. Egloff, R.L. Sargent, J.L. Hunt, R.R. Seethala, Mucoepidermoid carcinoma of upper aerodigestive tract: clinicopathologic study of 78 cases with immunohistochemical analysis of Dicer expression. Virchows Arch. 452, 629–635 (2008)PubMedCrossRef
21.
go back to reference W.M. Merritt, Y.G. Lin, L.Y. Han, L.Y. Han, A.A. Kamat, W.A. Spannuth, R. Schmandt, D. Urbauer, L.A. Pennacchio, J.F. Cheng, A.M. Nick, M.T. Deavers, A. Mourad-Zeidan, H. Wang, P. Mueller, M.E. Lenburg, J.W. Gray, S. Mok, M.J. Birrer, G. Lopez-Berestein, R.L. Coleman, M. Bar-Eli, A.K. Sood, Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 359, 2641–2650 (2008)PubMedCrossRefPubMedCentral W.M. Merritt, Y.G. Lin, L.Y. Han, L.Y. Han, A.A. Kamat, W.A. Spannuth, R. Schmandt, D. Urbauer, L.A. Pennacchio, J.F. Cheng, A.M. Nick, M.T. Deavers, A. Mourad-Zeidan, H. Wang, P. Mueller, M.E. Lenburg, J.W. Gray, S. Mok, M.J. Birrer, G. Lopez-Berestein, R.L. Coleman, M. Bar-Eli, A.K. Sood, Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 359, 2641–2650 (2008)PubMedCrossRefPubMedCentral
22.
go back to reference N. Kitagawa, H. Ojima, T. Shirakihara, H. Shimizu, A. Kokubu, T. Urushidate, Y. Totoki, T. Kosuge, S. Miyagawa, T. Shibata, Downregulation of the microRNA biogenesis components and its association with poor prognosis in hepatocellular carcinoma. Cancer Sci. 104(5), 543–551 (2013)PubMedCrossRef N. Kitagawa, H. Ojima, T. Shirakihara, H. Shimizu, A. Kokubu, T. Urushidate, Y. Totoki, T. Kosuge, S. Miyagawa, T. Shibata, Downregulation of the microRNA biogenesis components and its association with poor prognosis in hepatocellular carcinoma. Cancer Sci. 104(5), 543–551 (2013)PubMedCrossRef
23.
go back to reference Z. Shaikhibrahim, A. Lindstrot, J. Ochsenfahrt, K. Fuchs, N. Wernert, Epigenetics-related genes in prostate cancer: expression profile in prostate cancer tissues, androgen-sensitive and- insensitive cell lines. Int. J. Mol. Med. 31, 21–25 (2013)PubMedPubMedCentral Z. Shaikhibrahim, A. Lindstrot, J. Ochsenfahrt, K. Fuchs, N. Wernert, Epigenetics-related genes in prostate cancer: expression profile in prostate cancer tissues, androgen-sensitive and- insensitive cell lines. Int. J. Mol. Med. 31, 21–25 (2013)PubMedPubMedCentral
24.
go back to reference S.A. Melo, C. Moutinho, S. Ropero, G.A. Calin, S. Rossi, R. Spizzo, A.F. Fernandez, V. Davalos, A. Villanueva, G. Montoya, H. Yamamoto, S. Schwartz Jr, M. Esteller, A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 18, 303–315 (2010)PubMedCrossRef S.A. Melo, C. Moutinho, S. Ropero, G.A. Calin, S. Rossi, R. Spizzo, A.F. Fernandez, V. Davalos, A. Villanueva, G. Montoya, H. Yamamoto, S. Schwartz Jr, M. Esteller, A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 18, 303–315 (2010)PubMedCrossRef
25.
go back to reference N. Ameur, L. Lacroix, N. Motte, E. Baudin, B. Caillou, M. Ducreux, D. Elias, P. Chanson, M. Schlumberger, J.M. Bidart, Mutational status of EGFR, BRAF, PI3KCA and JAK2 genes in endocrine tumors. Int. J. Cancer 124, 751–753 (2009)PubMedCrossRef N. Ameur, L. Lacroix, N. Motte, E. Baudin, B. Caillou, M. Ducreux, D. Elias, P. Chanson, M. Schlumberger, J.M. Bidart, Mutational status of EGFR, BRAF, PI3KCA and JAK2 genes in endocrine tumors. Int. J. Cancer 124, 751–753 (2009)PubMedCrossRef
26.
go back to reference A. Boichard, L. Croux, A. Al Ghuzlan, S. Broutin, C. Dupuy, S. Leboulleux, M. Schlumberger, J.M. Bidart, L. Lacroix, Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J. Clin. Endocrinol. Metab. 97, E2031–E2035 (2012)PubMedCrossRefPubMedCentral A. Boichard, L. Croux, A. Al Ghuzlan, S. Broutin, C. Dupuy, S. Leboulleux, M. Schlumberger, J.M. Bidart, L. Lacroix, Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J. Clin. Endocrinol. Metab. 97, E2031–E2035 (2012)PubMedCrossRefPubMedCentral
27.
go back to reference M.D. Castellone, A. Verrienti, D.M. Rao, M. Sponziello, D. Fabbro, M. Muthu, C. Durante, M. Maranghi, G. Damante, S. Pizzolitto, G. Costante, D. Russo, M. Santoro, S. Filetti, A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with pheochromocytoma and medullary thyroid carcinoma: functional characterization. Clin. Endocrinol. 73, 529–534 (2010) M.D. Castellone, A. Verrienti, D.M. Rao, M. Sponziello, D. Fabbro, M. Muthu, C. Durante, M. Maranghi, G. Damante, S. Pizzolitto, G. Costante, D. Russo, M. Santoro, S. Filetti, A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with pheochromocytoma and medullary thyroid carcinoma: functional characterization. Clin. Endocrinol. 73, 529–534 (2010)
28.
go back to reference M. Sponziello, E. Lavarone, E. Pegolo, C. Di Loreto, C. Puppin, M.A. Russo, R. Bruno, S. Filetti, C. Durante, D. Russo, A. Di Cristofano, G. Damante, Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer. Endocrinology 154(9), 3043–3053 (2013)PubMedCrossRefPubMedCentral M. Sponziello, E. Lavarone, E. Pegolo, C. Di Loreto, C. Puppin, M.A. Russo, R. Bruno, S. Filetti, C. Durante, D. Russo, A. Di Cristofano, G. Damante, Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer. Endocrinology 154(9), 3043–3053 (2013)PubMedCrossRefPubMedCentral
29.
go back to reference F. Carlomagno, D. Salvatore, M. Santoro, V. de Franciscis, L. Quadro, L. Panariello, V. Colantuoni, A. Fusco, Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem. Biophys. Res. Commun. 207, 1022–1028 (1995)PubMedCrossRef F. Carlomagno, D. Salvatore, M. Santoro, V. de Franciscis, L. Quadro, L. Panariello, V. Colantuoni, A. Fusco, Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem. Biophys. Res. Commun. 207, 1022–1028 (1995)PubMedCrossRef
30.
go back to reference J.M. Thomson, M. Newman, J.S. Parker, E.M. Morin-Kensicki, T. Wright, S.M. Hammond, Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev. 20, 2202–2207 (2006)PubMedCrossRefPubMedCentral J.M. Thomson, M. Newman, J.S. Parker, E.M. Morin-Kensicki, T. Wright, S.M. Hammond, Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev. 20, 2202–2207 (2006)PubMedCrossRefPubMedCentral
32.
go back to reference P. Pallante, R. Visone, C.M. Croce, A. Fusco, Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Endocr. Relat. Cancer 17, 91–104 (2010)CrossRef P. Pallante, R. Visone, C.M. Croce, A. Fusco, Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Endocr. Relat. Cancer 17, 91–104 (2010)CrossRef
33.
go back to reference C.K. Chou, R.F. Chen, F.F. Chou, H.W. Chang, Y.J. Chen, Y.F. Lee, K.D. Yang, J.T. Cheng, C.C. Huang, R.T. Liu, miR-146b is highly expressed in adult papillary thyroid carcinomas with high-risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid 20, 489–494 (2010)PubMedCrossRef C.K. Chou, R.F. Chen, F.F. Chou, H.W. Chang, Y.J. Chen, Y.F. Lee, K.D. Yang, J.T. Cheng, C.C. Huang, R.T. Liu, miR-146b is highly expressed in adult papillary thyroid carcinomas with high-risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid 20, 489–494 (2010)PubMedCrossRef
34.
go back to reference D. Abraham, N.E. Jackson, J.S. Gundara, J. Zhao, A.J. Gill, L. Delbridge, B. Robinson, S. Sidhu, MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis and potential therapeutic targets. Clin. Cancer Res. 17, 4772–4781 (2011)PubMedCrossRef D. Abraham, N.E. Jackson, J.S. Gundara, J. Zhao, A.J. Gill, L. Delbridge, B. Robinson, S. Sidhu, MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis and potential therapeutic targets. Clin. Cancer Res. 17, 4772–4781 (2011)PubMedCrossRef
35.
go back to reference C. Mian, G. Pennelli, M. Fassan, M. Balistreri, S. Barollo, E. Cavedon, F. Galuppini, M. Pizzi, F. Vianello, M.R. Pelizzo, M.E. Girelli, M. Rugge, G. Opocher, MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Thyroid 22, 890–896 (2012)PubMedCrossRefPubMedCentral C. Mian, G. Pennelli, M. Fassan, M. Balistreri, S. Barollo, E. Cavedon, F. Galuppini, M. Pizzi, F. Vianello, M.R. Pelizzo, M.E. Girelli, M. Rugge, G. Opocher, MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Thyroid 22, 890–896 (2012)PubMedCrossRefPubMedCentral
36.
go back to reference M.T. Blahna, A. Hata, Regulation of miRNA biogenesis as an integrated component of growth factor signaling. Curr. Opin. Cell Biol. 25, 233–240 (2013)PubMedCrossRef M.T. Blahna, A. Hata, Regulation of miRNA biogenesis as an integrated component of growth factor signaling. Curr. Opin. Cell Biol. 25, 233–240 (2013)PubMedCrossRef
37.
go back to reference V. Besset, R.P. Scott, C.F. Ibáñez, Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J. Biol. Chem. 275, 39159–39166 (2000)PubMedCrossRef V. Besset, R.P. Scott, C.F. Ibáñez, Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J. Biol. Chem. 275, 39159–39166 (2000)PubMedCrossRef
39.
go back to reference J. Han, J.S. Pedersen, S.C. Kwon, C.D. Belair, Y.K. Kim, K.H. Yeom, W.Y. Yang, D. Haussler, R. Blelloch, V.N. Kim, Posttranscriptional crossregulation between Drosha and DGCR8. Cell 136, 75–84 (2009)PubMedCrossRefPubMedCentral J. Han, J.S. Pedersen, S.C. Kwon, C.D. Belair, Y.K. Kim, K.H. Yeom, W.Y. Yang, D. Haussler, R. Blelloch, V.N. Kim, Posttranscriptional crossregulation between Drosha and DGCR8. Cell 136, 75–84 (2009)PubMedCrossRefPubMedCentral
40.
go back to reference Y. Wang, R. Medvid, C. Melton, R. Jaenisch, R. Blelloch, DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. Nat. Genet. 39(3), 380–385 (2007)PubMedCrossRefPubMedCentral Y. Wang, R. Medvid, C. Melton, R. Jaenisch, R. Blelloch, DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. Nat. Genet. 39(3), 380–385 (2007)PubMedCrossRefPubMedCentral
41.
go back to reference Y. Han, Y. Liu, Y. Gui, Z. Cai, Inducing cell proliferation inhibition and apoptosis via silencing Dicer, Drosha, and Exportin 5 in urothelial carcinoma of the bladder. J. Surg. Oncol. 107, 201–205 (2013)PubMedCrossRef Y. Han, Y. Liu, Y. Gui, Z. Cai, Inducing cell proliferation inhibition and apoptosis via silencing Dicer, Drosha, and Exportin 5 in urothelial carcinoma of the bladder. J. Surg. Oncol. 107, 201–205 (2013)PubMedCrossRef
42.
go back to reference A. Jakymiw, R.S. Patel, N. Deming, I. Bhattacharyya, P. Shah, R.J. Lamont, C.M. Stewart, D.M. Cohen, E.K. Chan, Overexpression of Dicer as a result of reduced let-7 MicroRNA levels contributes to increased cell proliferation of oral cancer cells. Genes Chromosomes Cancer 49, 549–559 (2010)PubMedCrossRefPubMedCentral A. Jakymiw, R.S. Patel, N. Deming, I. Bhattacharyya, P. Shah, R.J. Lamont, C.M. Stewart, D.M. Cohen, E.K. Chan, Overexpression of Dicer as a result of reduced let-7 MicroRNA levels contributes to increased cell proliferation of oral cancer cells. Genes Chromosomes Cancer 49, 549–559 (2010)PubMedCrossRefPubMedCentral
Metadata
Title
Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation
Authors
Cinzia Puppin
Cosimo Durante
Marialuisa Sponziello
Antonella Verrienti
Valeria Pecce
Elisa Lavarone
Federica Baldan
Antonio Francesco Campese
Amelie Boichard
Ludovic Lacroix
Diego Russo
Sebastiano Filetti
Giuseppe Damante
Publication date
01-11-2014
Publisher
Springer US
Published in
Endocrine / Issue 2/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0204-3

Other articles of this Issue 2/2014

Endocrine 2/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.